The FDA has approved daraxonrasib for metastatic pancreatic ductal adenocarcinoma carrying a KRAS mutation, the gene fault present in roughly 90 percent of pancreatic cancers. KRAS makes a protein that acts as an on-off switch for cell growth. In these tumors it is stuck on. Older drugs couldn't grip the mutated protein's surface long enough to shut it off; daraxonrasib is a small molecule engineered to bind the mutant pocket and block the growth signal at the switch itself. In the trial that supported approval, patients on the drug had median overall survival roughly double that of patients on standard chemotherapy, the FDA's stated basis for clearance.

The stage here is a completed randomized trial feeding an actual regulatory approval, not a benchtop result waiting for one. That distinguishes it from most KRAS-inhibitor news of the last five years, which has mostly been about narrower mutations like G12C in lung cancer. Pancreatic cancer's five-year survival rate has sat near 13 percent for decades because tumors are usually caught late and chemotherapy buys months, not years. The next gate is durability: how long responding patients stay on the drug before the tumor evolves a resistance mutation in KRAS or a downstream pathway, which is the pattern that eventually blunted the earlier G12C inhibitors in lung cancer.